Regentis Biomaterials is a global biomaterials company dedicated to developing groundbreaking tissue repair solutions that restore the health and quality of life of patients.
The company’s current efforts are focused on orthopedic treatments using hydrogel implants to help regenerate damaged or diseased tissue. Gelrin© is the regenerative hydrogel platform for all product development.
This new generation of hybrid biomaterial is comprised of polyethylene glycol diacrylate (PEG-DA) and denatured fibrinogen. The PEG-DA produces a dense hydrogel network that is impermeable to cells while the denatured fibrinogen provides cleavage sites for enzymatic degradation. This unique combination provides synchronization between degradation of the implant and regeneration of new tissue.
Originally developed at the Technion - Israel Institute of Technology by Prof. Dror Seliktar, the patented Gelrin technology has potential as a development platform for diverse innovations.
The company’s first commercial product is GelrinC©, a cell-free, off-the-shelf injectable hydrogel for the treatment of painful injuries to articular knee cartilage. This cost-effective treatment offers orthopedic surgeons a simple to perform procedure while providing patients with sustained pain relief and function improvement.
Outcomes of a Phase I/II multi-center pilot study show substantial pain relief and significant improvement of function for the patients treated and followed up to date. MRI imaging shows that the GelrinC implant was replaced by full-thickness cartilage integrated into the surrounding bone and tissue. A strong improvement of the T2 signal intensity ratio displayed signal intensity similar to native cartilage, indicating formation of collagen type II rich tissue.
Regentis Biomaterials is actively involved in collaborations to research potential applications for the Gelrin platform, including Biodesign, a strategic alliance of global experts developing medicines that stimulate tissue regeneration. This coalition is supported by the European Commission as part of the Seventh Framework Programme (FP7).
Established in 2004, Regentis Biomaterials is a privately held company with offices in Princeton, New Jersey and Or Akiva, Israel. Regentis Biomaterials Investors include Medica Venture Partners, SPCVitalife, Royal DSM through its venturing subsidiary, the Crossroad Fund, Technion Investment Opportunities Fund, ProSeed and Shalom Equity Fund.
Caution: Investigational Device. Limited by U.S. law to investigational use.